OverviewSuggest Edit

ZIOPHARM Oncology is a biopharmaceutical company focused on the discovery and development of new cancer therapies. The Company's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. ZIOPHARM is applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
TypePublic
Founded2005
HQBoston, US
Websiteziopharm.com

Latest Updates

Employees (est.) (Feb 2020)73(+53%)
Revenue (FY, 2018)$146 K(-97%)
Share Price (Jun 2020)$3.3 (+3%)
Cybersecurity ratingBMore

Key People/Management at ZIOPHARM Oncology

Laurence J.N. Cooper

Laurence J.N. Cooper

CEO & Director
Chris Bowden

Chris Bowden

Director
Scott Braunstein

Scott Braunstein

Director
Chris Taylor

Chris Taylor

VP, Investor Relations and Corporate Communications
Heidi Hagen

Heidi Hagen

Director
Robert Hadfield

Robert Hadfield

EVP, General Counsel, Secretary AND Chief Compliance Officer
Show more

ZIOPHARM Oncology Office Locations

ZIOPHARM Oncology has an office in Boston
Boston, US (HQ)
1 1st Ave #34, Charlestown
Show all (1)

ZIOPHARM Oncology Financials and Metrics

ZIOPHARM Oncology Revenue

ZIOPHARM Oncology's revenue was reported to be $146 k in FY, 2018
USD

Net income (Q1, 2020)

(18.3m)

EBIT (Q1, 2020)

(18.7m)

Market capitalization (30-Jun-2020)

702.9m

Closing stock price (30-Jun-2020)

3.3

Cash (31-Mar-2020)

171.0m

EV

533.2m
ZIOPHARM Oncology's current market capitalization is $702.9 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

667.0k800.0k800.0k1.4m4.3m6.9m6.4m146.0k

Revenue growth, %

72%216%58%

General and administrative expense

15.0m19.5m15.7m12.2m17.6m14.4m14.8m19.9m

R&D expense

57.1m83.4m42.9m32.7m106.8m157.8m45.1m34.1m
Quarterly
USDQ3, 2010Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

200.0k200.0k200.0k200.0k200.0k200.0k200.0k200.0k200.0k200.0k633.0k272.0k272.0k1.9m2.0m1.7m1.6m1.6m1.6m1.6m146.0k

Cost of goods sold

5.7m9.1m10.7m

Gross profit

(8.9m)(10.5m)

Gross profit Margin, %

(4462%)(5233%)
USDQ3, 2010

Financial Leverage

1.6 x
Show all financial metrics

ZIOPHARM Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

ZIOPHARM Oncology Online and Social Media Presence

Embed Graph

ZIOPHARM Oncology News and Updates

Ziopharm Oncology Announces Recent Publications in Peer-Reviewed Scientific Journals

– Encouraging long-term outcome data after infusion of Sleeping Beauty-modified CAR-T published in Blood –

Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast

BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Ja…

Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects –

Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast

BOSTON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019, beginning at…

Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019

BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended September 30, 201…
Show more

ZIOPHARM Oncology Blogs

Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update

– Regulatory discussions with FDA advance Ziopharm TCR-T IND process – – Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® ; Controlled IL-12 clinical data update at ASCO 2020 – – Work restrictions at NCI and MD Anderson impacting clinical trials; Ziopharm

Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting

BOSTON , April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the treatment

Ziopharm Oncology to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 7, 2020

BOSTON , April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the first quarter ended March 31, 2020 .

Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019

– Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 – – Clinical trial milestones and data readouts in 1H20 –   – Company to host conference call and webcast today at 4:30

Ziopharm Oncology Presentation at the Barclays Global Healthcare Conference to be Webcast

Ziopharm Oncology Presentation at the Barclays Global Healthcare Conference to be Webcast Content Import Fri, 02/28/2020 - 08:31 Ziopharm Oncology Presentation at the Barclays Global Healthcare Conference to be Webcast Feb 28, 2020 This release is a backfill …

Ziopharm Oncology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 2, 2020

Ziopharm Oncology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 2, 2020 Content Import Mon, 02/24/2020 - 08:31 Ziopharm Oncology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 2, 2020 Feb 24, 2020 …
Show more

ZIOPHARM Oncology Frequently Asked Questions

  • When was ZIOPHARM Oncology founded?

    ZIOPHARM Oncology was founded in 2005.

  • Who are ZIOPHARM Oncology key executives?

    ZIOPHARM Oncology's key executives are Laurence J.N. Cooper, Chris Bowden and Scott Braunstein.

  • How many employees does ZIOPHARM Oncology have?

    ZIOPHARM Oncology has 73 employees.

  • What is ZIOPHARM Oncology revenue?

    Latest ZIOPHARM Oncology annual revenue is $146 k.

  • What is ZIOPHARM Oncology revenue per employee?

    Latest ZIOPHARM Oncology revenue per employee is $2 k.

  • Who are ZIOPHARM Oncology competitors?

    Competitors of ZIOPHARM Oncology include Novocodex Biopharmaceuticals, Maijing Gene and Arbutus Biopharma.

  • Where is ZIOPHARM Oncology headquarters?

    ZIOPHARM Oncology headquarters is located at 1 1st Ave #34, Charlestown, Boston.

  • Where are ZIOPHARM Oncology offices?

    ZIOPHARM Oncology has an office in Boston.

  • How many offices does ZIOPHARM Oncology have?

    ZIOPHARM Oncology has 1 office.